Eli Lilly and Company
LLY Healthcare Drug Manufacturers - General NYSE
$917.23
$-4.25 (-0.46%)
Open: $929.49 | High: $929.49 | Low: $911.89 | Prev Close: Prev Close: $921.48
Market Cap: $866.62B
Volume: 1.6M | Avg: 3.1M
Last updated: April 24, 2026 at 02:03 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 617
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 39.98 |
| P/B Ratio | 31.04 |
| P/S Ratio | 13.30 |
| EPS | $22.94 |
| Beta | 0.50 |
| Shares Outstanding | 944.82M |
| 52-Week High | $1133.95 |
| 52-Week Low | $623.78 |
| SMA 50 | $965.76 |
| SMA 200 | $907.42 |
| Dividend Yield | 0.68% |
| Annual Dividend | $6.23 |
| Next Earnings | April 30, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 83.8% |
| Operating Margin | 45.6% |
| Net Margin | 31.7% |
| ROE | 97.9% |
| ROA | 18.3% |
| Debt/Equity | 1.60 |
| Current Ratio | 1.58 |
| Quick Ratio | 1.19 |
Balance Sheet
| Total Assets | $112.48B |
| Total Liabilities | $85.94B |
| Total Equity | $26.54B |
|
|
|
| Cash | $7.16B |
| Total Debt | $42.50B |
| Net Debt | $35.34B |
Income Statement
| Revenue | $65.18B |
| Gross Profit | $54.62B |
| Operating Income | $29.70B |
| Net Income | $20.64B |
|
|
|
| EBITDA | $27.94B |
| Revenue/Share | $72.58 |
Cash Flow
| Operating CF | $16.81B |
| CapEx | $7.84B |
| Free Cash Flow | $8.97B |
|
|
|
| Book Value/Share | $29.55 |
| Tangible Book/Share | $15.72 |
| Equity/Share | $29.55 |
Technical Indicators
| RSI (14) | 55.78 Neutral |
| MACD |
-14.31
Signal: -17.69
|
| Volatility | 31.94% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +18.21% |
| Sharpe Ratio | 0.62 Fair |
| Volatility (Ann.) | 37.27% Moderate |
| LLY (1Y) | +18.21% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | +3.81% |
Sector Comparison (Healthcare)
| Metric | LLY | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 39.98 | 25.96 | 80% |
| P/B Ratio | 31.04 | -21.65 | 96% |
| ROE (%) | 97.85% | -11.89% | 98% |
| Net Margin (%) | 31.66% | 8.99% | 96% |
| Stock Score | 617 | 547.0 | 82% |
| 1Y Return (%) | +18.21 % | +4.87 % | 76% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $917.23 | $917.82 | $922.66 | $923.72 | $972.74 | $905.57 | 55.78 | -14.31 | 31.94% | 2149232 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the LLY stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| LLY | Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)? | Neutral | fool.com | Read More |
| LLY | Why Eli Lilly Stock Flopped on Friday | Neutral | fool.com | Read More |
| LLY | Eli Lilly: A Heavyweight Battle Isn't Won In Round 1 | Neutral | seekingalpha.com | Read More |
| LLY | Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake | Negative | invezz.com | Read More |
| LLY | Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race | Negative | gurufocus.com | Read More |
Recent Insider Trading
No recent insider trading data available for LLY
Company Information
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| CEO | David A. Ricks |
| Employees | 47000 |
| Country | US |
| IPO Date | 1972-06-01 |
| Exchange | NYSE |
| Website | https://www.lilly.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category